#Biotech Company

Zymeworks aims to raise $100M in public offering amid leadership shakeup

Zymeworks is looking to raise $100 million in a public offering, barely a week since new CEO Kenneth Galbraith took the reins of the biotech company, which has operations in Seattle and Vancouver, B.C. Last week, Galbraith announced workforce cuts and changes in leadership as the company focuses on a phase 3 trial for one of its anti-cancer agents and early clinical testing of another. The company priced shares yesterday at around $8, far below the high of more than $50 in January 2021. Zymeworks reported $250 million in cash, cash equivalents and short-term investments at the end of 2021. Shares were down more than 10% Thursday.
Picture for Zymeworks aims to raise $100M in public offering amid leadership shakeup

Intellia: Best All-Around Gene Editing Company

Intellia is considered the best gene editing company because of its first mover status in the use of in vivo gene editing technology. The reason why aggressive growth investors should buy the stock of Intellia (NASDAQ:NTLA) is because the company is considered the best gene editing company because of its first mover status in the use of in vivo gene editing technology. There are two different ways that gene editing technology like CRISPR can be used, which are in vivo approaches and ex vivo approaches. In vivo gene therapy is the preferred strategy by most scientists because in vivo methods have the ability to reduce the time and resources needed for treatment for diseases with a genetic cause.
Picture for Intellia: Best All-Around Gene Editing Company
Motley Fool

Why Epizyme Stock Plummeted by 44% Today

One of the steepest decliners in the biotech sector Thursday was Epizyme (NASDAQ:EPZM). The cancer-focused biotech saw its shares plummet 44% in value that day, on news of a dilutive secondary stock issue. So what. Epizyme announced that it is floating nearly 56.7 million shares of its stock, which will...
MedCity News

Biotech startup Septerna lands $100M to break new ground on an old drug target

For scientists developing new drugs, it’s hard to go wrong targeting a family of receptors that regulate virtually every known process in human beings. G protein-coupled receptors (GPCRs) are found throughout the body, and research into their roles has yielded an estimated 700 FDA-approved drugs so far. But that productivity comes with a problem. With so many molecules already targeting these receptors, it’s harder for scientists to find new ways and new places to hit them.

IVDiagnostics names new CEO

IVDiagnostics has named a new CEO. The company picked Sarah Ware to replace outgoing CEO Luis Nunez. “Her knowledge and expertise in developing commercially viable diagnostic tests was a key factor in determining our next chief executive officer," Co-Founder and Chairman Frank Szczepanski said. Long based at the Purdue Technology...

Jupiter Neurosciences aims to raise up to $20.24M in IPO

Jupiter Neurosciences (NASDAQ:JUNS) has set terms for an initial public offering of its stock, aiming to raise up to $20.24M from the deal. The biotech company said in a filing that it intends to offer 2.2M units, or 2.53M if the underwriters’ over-allotment option is fully exercised, for $6 to $8 per unit. Each unit will consist of one share plus one warrant to purchase one share at the IPO price.

7 Worst SPACs for Smart Investors to Skip in 2022

Special purpose acquisition companies (SPACs) have had a dreadful past six months. After a big run in the early part of 2021, the market became flooded with SPACs. As economics predict, when the supply of something greatly exceeds demand, the price plunges. Too many SPAC sponsors were looking for a quick paycheck and launched shoddy deals at the height of the mania.
Investor's Business Daily

Why Vertex Pharmaceuticals' Strong Outlook Wasn't Enough To Spark Shares

Vertex Pharmaceuticals (VRTX) issued a bullish outlook for 2022 on Wednesday, but VRTX stock remained muted in late action. The biotech company guided to $8.4 billion to $8.6 billion in full-year sales — well above analysts' forecast for $8.2 billion. But investors in VRTX stock are eagerly awaiting additional developments for Vertex's non-cystic fibrosis programs, an area where the company has the largest market share.

Moderna’s special booster dose is coming to compete with Omicron variants, company’s trial begins

Covid-19 Vaccine: The Omicron variant of Kovid-19 is spreading rapidly all over the world. Meanwhile, American biotech company Moderna announced on Wednesday that it has started clinical trials of a booster dose of a vaccine designed specifically to combat the Omicron variant of the corona virus. Is done. A total of 600 adults will be involved in the trials. Half of these have received two doses of Moderna’s Kovid-19 vaccine at least 6 months ago. While half have received a pre-authorized booster dose with two doses.

Amarin gains as activist Sarissa raises stake

Amarin Corporation (NASDAQ:AMRN) is trading ~3.7% higher in the pre-market on below-average volume after Sarissa Capital increased its holding in the biotech company to ~6.1% from ~2.2% previously. According to a 13-D filing submitted Monday, the activist investor has executed multiple transactions to boost its stake, the last of which...
Seeking Alpha

Alector, Inc: A Newer Biotech Company With Big Potential

Biotech companies have seen an economic boom lately thanks to the COVID-19 Pandemic and the need for effective treatments. Alector, Inc. (NASDAQ: ALEC) is one of the freshest faces in the biotech industry, having only been taken public in February of 2019. While many of its successful counterparts have thrown themselves into the pandemic-driven fray, Alector has made its mark by offering potential revolutionary advances to the treatment of neurodegenerative diseases, a lucrative pocket in the medical market desperate for advancement. A deal with GlaxoSmithKline (NYSE: GSK) in July 2021 for a breakthrough monoclonal antibody treatment saw stock prices soar. However, since that announcement, Alector has underperformed, seeing its stock prices fall back down to earth despite showing promising earnings results in Q3 2021.

Why Mind Medicine Shares Are Rising Today

Mind Medicine Inc (NASDAQ: MNMD) is trading higher Tuesday morning after the company announced the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application, allowing its Phase 2b dose-optimization trial of MM-120 for the treatment of generalized anxiety disorder to proceed. The previously announced clinical hold...


DAVIS, Calif., Jan. 25, 2022 /CNW/ -- ELEVAI LABS, INC., ("ELEVAI" or the "Company") a biotech company leveraging the power of human stem cell exosomes to create next-generation topical skincare products, is pleased to announce that the company has won the LaunchPad SBDC People's Choice Award at the 2022 Octane Aesthetics Tech Summit ("ATS") held in Newport Beach, California.

Halberd CEO Letter: 2021 Year-End & 2022 Outlook (HALB)

Jackson Center, Pennsylvania–(Newsfile Corp. – January 25, 2022) – Greetings From The CEO And Staff At HALBERD CORPORATION(OTC Pink: HALB)!. First of all, I want to wish all of our shareholders and constituents a Very Healthy, Happy and Prosperous New Year!. 2021 OVERVIEW AND ACHIEVEMENTS. Halberd continued...

Short Interest in Ensysce Biosciences, Inc. (NASDAQ:ENSC) Declines By 86.8%

Ensysce Biosciences, Inc. (NASDAQ:ENSC) was the recipient of a significant drop in short interest in the month of January. As of January 15th, there was short interest totalling 106,000 shares, a drop of 86.8% from the December 31st total of 801,600 shares. Based on an average trading volume of 0 shares, the short-interest ratio is currently ∞ days.